In stealth
EntangleBio makes multi‑gene disease discoverable.
We are a quantum network medicine company. We're working with a group of scientific and data collaborators to find the gene combinations behind disease.
Spun out of the Ludwig Boltzmann Institute for Network Medicine, Vienna · Cleveland Clinic Quantum Innovation Catalyzer 2026
01The problem
When a single gene is the cause, rapid genome sequencing can turn an emergency into a treatment within hours.
Today, 43% of critically ill babies get an answer this way.
But what about the other 57%?
Hundreds of millions of people live with diseases that no single genetic variant can explain alone.
Sources: WHO, Diabetes (2024); NHGRI, Complex Disease.
In many cases, the combined effect of several variants can.
But the search space is enormous and noisy.
Possible combinations of ~20,000 human protein-coding genes.
There is no scalable way to search it today.
EntangleBio solves this.
02Approach
We find multi-gene disease mechanisms systematically.
We combine network medicine, the map of how genes and proteins interact, with quantum and quantum-inspired algorithms that search that map for the combinations of variants that drive disease.
Input
Patient and control genomics plus a disease-relevant biological network.
Search
Find gene combinations linked to the disease and the functional modules they disrupt.
Interpret
Identify the shared mechanism, the patient group and a potential intervention point.
We identify the gene combinations that matter, the patients who share them, and where treatment can intervene.
This unlocks
Better patient stratification
Group patients by shared mechanism, not by symptom.
New therapeutic targets
Find intervention points that single-gene analysis misses.
Drug repurposing
Match existing drugs to newly explained patient groups.
The science behind disease modules: Menche et al., Science 2015
03Where we are
We model gene combinations the way physicists model electron interactions.
We express the search as a
guided fermionic Hamiltonian problem.
The mathematical framework behind molecular simulation, and one of quantum computing's most promising applications.
Classical today
Our engine already searches gene pairs on classical computers.
Quantum as complexity grows
A credible path to quantum advantage for larger networks and higher-order combinations.
- ConceptNetwork medicine meets quantum-inspired search
- Working methodTwo-gene signals found in simulated data
- First quantum runAugust 2026 · IBM Heron · 156 qubits
- Real-patient validationNext, with partners
04Ecosystem
Built with the institutions that defined network medicine and are bringing quantum computing to health.
Cleveland Clinic
Selected for the 2026 Quantum Innovation Catalyzer Program, Cleveland Clinic's 12-month program for quantum applications in healthcare. Cleveland Clinic is also an investor.
About the Catalyzer programIBM Quantum
Access to IBM quantum hardware through the Catalyzer, including IBM Quantum System One at Cleveland Clinic, the first quantum computer dedicated to healthcare and life-sciences research, and the 156-qubit IBM Heron r2 processor.
Cleveland Clinic and IBM unveil the first quantum computer dedicated to healthcare researchLudwig Boltzmann Institute for Network Medicine
EntangleBio is a spin-off with IP from the Ludwig Boltzmann Institute for Network Medicine at University of Vienna.
LBI Network Medicine on the 2026 Quantum Innovation Catalyzer Program05Team
We built the field of network medicine. And commercialized it before.
Joseph Loscalzo, MD, PhD
Core Scientific Advisor
- Hersey Professor at Harvard Medical School
- Created network medicine as a field of biomedical research
- 1,200+ publications and 33 patents
Jörg Menche, PhD
Scientific Co-founder
- Founding Scientific Director at LBI for Network Medicine
- First author of the landmark Science disease-module paper
- Professor at University of Vienna and Max Perutz Labs
Péter Ruppert
Co-founder & CEO
- Co-founded Scipher Medicine
- Co-founded Foodome (acquired by Viome)
- EIR at Northeastern University / Center for Complex Network Research (CCNR)
Joel Hancock
Chief Technology Officer
- Oxford Mathematics
- PhD candidate in mathematics of network science
- Main author of core company patent underway
A team of scientists and builders already in place.
Markus Kirolos Youssef
Quantum Algorithm Researcher
- PhD in mathematics: applied topology for biological network analysis
- Network biology research at CeMM, BSC and EPFL
- Multi-omics bioinformatics pipelines at UNIL and FIMM
Julia Hepp, PhD
Business Development & Partnerships
- €400M+ in deals delivered
- 25+ years of business development experience
- Key representation to pharma and gene therapy companies
Levente Kovacsik
Chief Strategy & CorpDev Officer
- Former DeepTech VC, 6 deals in life sciences
- Co-founded an IP-tech startup
- Developed an ML model to predict DeepTech venture outcomes
Florina Daniela Ungureanu
Operations and Grants Associate
- Ran an incubator program at a research institute
- Won and implemented European grants & tenders
- Ecosystem partnerships at a DeepTech venture builder
06Collaborate
We are looking for collaborators.
We want to work with:
- Clinicians and PIsWith cohorts or families where single-gene analysis leaves patients unexplained, including incomplete penetrance and unsolved exomes.
- Biobanks and data ownersWith exome or genome data plus phenotypes. We can work inside your secure environment; your data does not need to leave it.
- Disease expertsWho can validate candidate mechanisms in the lab or the clinic.
- Quantum and computational scientistsInterested in network and combinatorial problems on real hardware.
What collaborators get: joint publications, early access to findings in their disease area, and a scientific partner that brings the method and the compute.
Two ways to reach us